Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Liquidia Technologies Announces Expansion of Series C Financing

Abstract:
PPD Joins as New Investor, Increases Series C Financing to $25 Million

Liquidia Technologies Announces Expansion of Series C Financing

Research Triangle Park, NC | Posted on April 20th, 2010

Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that it has added an additional investor, PPD, Inc., to its Series C financing. The final addition of PPD brings the total funding for this round to $25 million. The initial Series C closing was announced in January 2010.

"The vaccines market is one of the fastest growing segments in the industry, and it is an area where PPD has strong laboratory and clinical development expertise," said David L. Grange, Chief Executive Officer of PPD. "Liquidia's novel vaccines and therapeutics have the potential to address a range of diseases, and we believe its PRINT® technology offers a unique solution for improving vaccine safety and efficacy."

PPD, a leading global contract research organization, joins Canaan Partners, New Enterprise Associates, Morningside Venture Investments Limited, Pappas Ventures and Firelake Capital as investors in the Series C round.

"Given PPD's broad expertise in vaccine and biologic drug development, this was a compelling opportunity for both parties," said Neal Fowler, Chief Executive Officer of Liquidia Technologies. "The addition of PPD as an investor provides further resources for rapidly advancing our product pipeline and reinforces the potential of our disruptive technology platform."

Proceeds from the financing will be used to accelerate Liquidia's lead vaccine candidate through initial clinical studies and expand development of particle-based solutions for novel vaccines and therapeutics.

####

About Liquidia Technologies
Liquidia Technologies is developing precisely engineered particles for improved delivery of biological and small molecule therapeutics within the initial fields of vaccines, nucleic acid delivery and inhaled therapeutics. The ability to control particle design parameters such as size, shape and composition is allowing Liquidia to address critical unmet needs in the prevention and treatment of human disease. The company was founded in 2004 and is located in Research Triangle Park, North Carolina.

For more information, please click here

Contacts:
Elle Pishny
919-328-4361

Copyright © Liquidia Technologies

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Iranian Scientists Use Artemisia Annua Plant to Produce Breast Cancer Drugs August 29th, 2015

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

A new technique to make drugs more soluble August 28th, 2015

Nanocatalysts improve processes for the petrochemical industry August 28th, 2015

Investments/IPO's/Splits

Nanometrics to Participate in the Citi 2015 Global Technology Conference August 26th, 2015

Nanostart AG: First-half figures 2015 published and new supervisory board elected : Publication of first-half figures 2015 - Shareholders' meeting elected new supervisory board August 22nd, 2015

Harris & Harris Group Portfolio Company, AgBiome, Secures $34.5 Million Series B Financing Led By Bill and Melinda Gates Foundation August 20th, 2015

Harris & Harris Group Reports Financial Statements as of June 30, 2015, and Announces a Stock Repurchase Program August 10th, 2015

Nanomedicine

Iranian Scientists Use Artemisia Annua Plant to Produce Breast Cancer Drugs August 29th, 2015

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

A new technique to make drugs more soluble August 28th, 2015

These microscopic fish are 3-D-printed to do more than swim: Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities August 26th, 2015

Announcements

Iranian Scientists Use Artemisia Annua Plant to Produce Breast Cancer Drugs August 29th, 2015

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

A new technique to make drugs more soluble August 28th, 2015

Nanocatalysts improve processes for the petrochemical industry August 28th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic